India, Developing Nations To Press Third-World Disease Drugs At WHO Meeting (India)
This article was originally published in PharmAsia News
Executive Summary
India and other developing nations plan to make a strong case in an April international lobbying effort for funding drugs aimed at some of the diseases plaguing their segment of the world. Diseases in the developing world, such as tuberculosis and malaria, comprise less than 10 percent of research dollars spent on drug research even though those diseases account for more than 90 percent of the diseases afflicting the world's population. The World Health Organization's decision-making body has scheduled international negotiations in Switzerland in April to hear from participating nations on the issue. (Click here for more
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.